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for health benefits in the same cohort.1 We did not observe a
dose-response relationship betweenmoderate-intensity and
vigorous-intensityphysical activityandall-causemortality risk
in “insufficiently activeweekendwarriors”who reported 1 or
2 sessions per week but did not meet physical activity guide-
lines of at least 150 minutes per week of moderate-intensity
aerobic activity or at least 75 minutes per week of vigorous-
intensity aerobic activity.We did observe a linear trendwhen
investigating total physical activity of any intensity. We con-
cluded that someof thehealth benefitsmight be explainedby
nonexerciseactivity, suchas light-intensitywalking.More than
40% of the weekend warriors were in desk-bound occupa-
tions, andwewould suggest that participation in sport andex-
ercise at theweekend is enough to increase cardiorespiratory
fitness and to reduce the mortality risk associated with the
sedentary lifestyle of Western societies.
WethankLamandcolleagues for their letter too.Theysug-
gested that air pollution was subject to geographical varia-
tion and that air pollution was a relevant confounding vari-
able.Wedidnot adjust for air pollution;however, theavailable
evidence suggests that air pollution is only related to lungcan-
cer mortality.2 Lam and colleagues also suggested that treat-
mentavailabilitywassubject togeographicalvariationandthat
treatment availability was also a pertinent confounding vari-
able. There is someevidenceof aNorth-Southdivide inhealth
care in the United Kingdom; however, socioeconomic factors
may explain differences in physical activity3 and other expo-
sures and outcomes.4,5 Compared with the inactive partici-
pants in our study, the hazard ratio for cancer mortality was
0.79 (95%CI, 0.66-0.94) in the regularly active and0.82 (95%
CI,0.63-1.06) in theweekendwarriorsafter adjustment forage,
sex, smoking habit, longstanding illness, and socioeconomic
status (the regularly active reported≥150minutes/wk inmod-
erate-intensity aerobic activityor≥75minutes/wk invigorous-
intensity aerobic activity from≥3 sessions; theweekendwar-
riors reported the same amounts of activity per week from 1
or 2 sessions). Lam and colleaguesmentioned a clustering ef-
fect in our subsample. The core sample is weighted so that it
might be representative of the population living in private
households.6 When we have weighted the subsample, it has
had little bearing on the association between physical activ-
ity and mortality.
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Discrepant Expectations About Benefits andHarms
To the Editor The systematic reviewbyHoffmann andDelMar1
in a recent issue of JAMA InternalMedicine showed robust but
sad evidence that most health care professionals divergently
misconceive benefits and harms of their interventions (treat-
ments, screenings, tests) and deserves comment.
First, the various explanations have overlooked (1) an en-
during but obvious innumeracy2 and (2) illiteracy that is not
openly acknowledged. In their review,HoffmannandDelMar
rightly used the terms “benefits” and “harms,” but PubMed
searchresults reach2818for“benefit-risk”and1159for“benefit/
risk” vs 8 for “potential benefit” and “risk of harm” com-
bined, 123 for“benefit-harm,”and33 for“benefit/harm.”When
health care professionals intervene, benefits are guaranteed
while harms are only a “potential risk”.
Second, solutions for shared decision making with
patients should have been mentioned. For example,
evidence-based tools with simple pictographs showing
absolute numbers and consistent denominators (ie, per
1000 persons), time frames, and visuals using the same
scale for information on benefits and harms of the options
would have been helpful,3 as would resources like the
Patient-CenteredOutcomesResearchTrust Fund (http://www
.pcori.org/research-results/2013/development-and-user-
testing-decision-aid-ventricular-assist-device-placement) and
theHardingCenter forRiskLiteracy (https://www.mpib-berlin
.mpg.de/en/research/harding-center) which provide patient
independence through risk assessment, a critical issue.4
SHARE-IT (http://magicproject.org/research-projects/share-
it/) isaproject still indevelopmentandwronglyuses thebenefit
and/or risk semantics.
Last, underestimation of harms and overestimation of
benefits is a much wider problem. Regulatory agencies
grant market approvals for drugs faster and faster on surro-
gate end points without clinical relevance while market
withdrawal is often unreasonably delayed, even in the case
of drug-related deaths.5
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To the Editor We appreciate the systematic review by
HoffmannandDelMar1 ina recent issueofJAMAInternalMedi-
cineestimating theaccuracyofphysicians’expectationsofben-
efits and harms and worry with them that inaccuracies may
lead to suboptimal medical care. Nonetheless, we are con-
cerned that their approachmight obscure rather than illumi-
nate themeasurement of physicians’ predictive accuracy and
its implications.
Surveys andquestionnaires based on clinical vignettes or
“typical patients”provideuswith ameasureof agreementbe-
tween clinician estimates and those published in the litera-
ture for standard target populations. This information is im-
portant because it tells us about clinicians’ awareness—and
perhapsacceptance—of relevant researchdata.However, there
are 2main reasons why these kinds of studies ought to be in-
terpreted as rough indicators and do not necessarily answer
the question of whether clinicians truly tend to underesti-
mate harms and overestimate benefits as the authors con-
clude.
First, there is increasing recognition that the degree of
transportability of research estimates to different popula-
tions and settings, as well as their stability over time, cannot
be taken for granted.2,3While in somecases this concernmight
be addressed by accepting a credible range surrounding the
point estimate, in other cases it might be safer not to assume
transportability and further investigate variance in local base
ratesbefore inferring inaccuracy fromthepresenceofhighvari-
ance in clinicians’ predictions.4
Second, because expectations of benefit and harm are in
practice relative to actual patients with various idiosyncra-
sies and real settings, physicians’ predictive accuracy ought
to be estimated in the field.5While the accuracy of physicians
as a group can be measured cross-sectionally with respect to
a theoretical reference standard, for purposes of service im-
provement it might be farmore informative to investigate in-
dividual physicians’ calibration longitudinally by generating
a track record of correct or incorrect predictions for samples
of patients with particular conditions.
Of course, we accept that the study of physicians’ risk es-
timates in the real word is more complicated and expensive
than relying on theoretical cases.However, if our aim is to im-
prove medical care, our actions ought to be informed by rel-
evant and methodologically sound evidence, which is, after
all, the central premise behind the systematic review by
Hoffmann and Del Mar.1
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In ReplyWethankDrBraillon forhis comments. First,weagree
that innumeracy and naiveté about clinical epidemiology
concepts are some of the underlying contributions to the
misperceptions that we report in our systematic review.1 Cli-
nician illiteracy in health statistics has been articulated
previously.2,3 However, we disagree that the benefits of
interventions are certain while the harms are only a poten-
tial risk. Few interventions have certain benefits: there is
both the chance of benefit and the chance of harm from
most interventions.
Second,weagree, aswemention inourarticle,1 that shared
decision making is part of the solution. While there are vari-
ous risk communication strategies, tools, and resources that
can be used to facilitate this, word limits precluded us from
elaborating on these. Finally, we also agree that the issue of
accurate knowledge about intervention benefit and harm ex-
tendsbeyondclinicians’ knowledge and is influencedbywhat
occurs (or does not occur) in other contexts, such as regula-
tory agencies, and the phases before the research knowledge
filters to clinicians. Efficient access to accurate and up-to-
date knowledge about interventionbenefits andharms is des-
perately needed because current knowledge generation and
dissemination systems are flawed and a patchwork of reac-
tive and ad hoc solutions.
We also thank Drs Sepulveda and Fuller for their com-
ments and concerns about theuseof clinical vignettes in some
of the primary studies included in our review.1 We agree that
such responses provide information about clinician aware-
ness, and possibly acceptance, of research data about benefits
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andharms,but that“realworld”useof suchdataare tricky, and
some caution is needed when considering extrapolating from
research estimates to other settings and populations. We ac-
knowledge that the idealmethod for assessing the accuracy of
people’s riskperceptionestimateshavenotbeen identifiedand
that across the studies included in our review,1 and our review
of patient expectations,4 a variety ofmethods tomeasure this
wereused,mostofwhichareunvalidatedandsuggest thatmore
research evaluating variousmethods is needed.
ThesecondcommentbyDrsSepulvedaandFuller—thatcol-
lectingdata fromreal settings,presumably fromrecordingwhat
clinicians predict about the likely benefits and harms of clini-
cal management options under consideration with actual pa-
tients—isaninteresting ideatoexplorewithresearch.Oursearch
foundnostudies thatusedanapproachlikethis.Thearticle they
cite as anexemplar5 (whichstudied thediagnostic abilityof cli-
nicians inanemergencydepartmentorurgentcareclinic todis-
tinguish influenza frominfluenzalike illness, andcomparedthe
performance of clinical judgement, a rapid diagnostic test and
aclinicalpredictionrule,againsta laboratorygoldstandard)does
notmeasure quantification of the benefits or harms of clinical
management;hence this studydoesnotmeet thecriteria for in-
clusion in our systematic review.1
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Facts Concerning Duexis PrescribingHabits Related
to Combination Therapies
To theEditor In theirViewpointabouthighprices fordrugswith
genericalternativesspecificallycitingDuexis (HorizonPharma)
published in a recent issue of JAMA InternalMedicine, Hakim
and Ross1 omitted important facts about Duexis and physi-
cian prescribing habits related to combination therapies.
AlthoughHakimandRosscorrectlynotedthatDuexis isap-
proved for the relief of signs and symptoms of rheumatoid
arthritis and osteoarthritis and to decrease the risk of devel-
oping upper gastrointestinal ulcers in patients who are tak-
ing ibuprofen for those indications, their Viewpoint1 created
the misperception that the medication is a simple combina-
tion of 2 readily available medicines. In fact, Duexis is spe-
cially formulated to contain prescription strength ibuprofen
and a protective core of famotidine at a higher dose because
standard doses fail to provide gastric protection.2 The US
Food and Drug Administration approved Duexis based on 2
randomized phase 3 clinical studies that enrolled more than
1500 patients.3
Moreover, the authors did not mention that the approval
of Duexis marked a new indication for famotidine.3 Previ-
ously, famotidinewasnot approved todecrease the risk of de-
veloping upper gastrointestinal ulcers in patients taking ibu-
profen or any other nonsteroidal anti-inflammatory (NSAID).
Indeed, famotidine is stillnotapprovedasastandalonetherapy
or in combination with another active ingredient for this use
(except in Duexis). There is no approved generic, over-the-
counter,orclinicallyequivalentmedicineexceptDuexis,which
has been shown to provide gastroprotection.
Byproviding the benefits of anNSAIDanda gastroprotec-
tive medicine to reduce NSAID-induced upper gastrointesti-
nal ulcers in a single pill, the risk of patient nonadherence for
gastrointestinalprotection is reduced.Data showthat less than
25%of physicians coprescribe anNSAIDandamedicine to re-
duce the frequency of the ulcers they may cause.4
The article alsomisstatesHorizonPharma’smeans of dis-
tributing itsmedicines.HorizonPharmahasneverowned,does
not currently own, and has no option to purchase any phar-
macies. In the first half 0f 2016, our primary care medicines,
includingDuexis,weredispensedbyapproximately20000re-
gional, local, and retail pharmacies.
As the health care system becomes increasingly complex,
Horizon Pharma considers it our responsibility to ensure that
patients receive the medicine their physicians prescribe and
eliminatebarriers toaccess.Wehopethat important topicssuch
as patient access, clinical relevance, and unmet medical need
again become the primary focus of the dialogue to enable phy-
sicians tomake appropriate clinical decisions.
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